64 completed, 2 terminated, 1 withdrawn. 34 Phase 3, 16 Phase 4, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 34 | Completed 33, Withdrawn 1 |
| Phase 4 | 16 | Completed 15, Terminated 1 |
| Phase 2 | 10 | Completed 9, Terminated 1 |
Follow Acellular Pertussis: new trials by email Literature Review of Acellular Pertussis trials Research Report on Acellular Pertussis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants Infanrix-IPV/Hib - Diphtheria, Acellular Pertussis | Phase 3 | Withdrawn | GlaxoSmithKline | 2017-12-01 | 2017-12-26 | |
| Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Infanrix hexa - Diphtheria, Hepatitis B | Phase 4 | Completed | GlaxoSmithKline | 551 | 2016-09-19 | 2020-01-14 |
| Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Infanrix hexa, Prevnar13 - Acellular Pertussis, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 601 | 2016-01-22 | 2019-07-09 |
| Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. Pertussis maternal immunization - Diphtheria, Acellular Pertussis | Completed | GlaxoSmithKline | 1 | 2015-10-01 | 2024-02-22 | |
| Duration of Protection: GSK DTaP Vaccines Infanrix, Pediarix, Kinrix - Diphtheria, Acellular Pertussis | Completed | GlaxoSmithKline | 1 | 2015-02-01 | 2015-11-02 | |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Infanrix hexa, Pediarix, ActHIB - Poliomyelitis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 585 | 2014-04-16 | 2019-11-27 |
| Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children Boostrix™ - Diphtheria, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 302 | 2014-02-22 | 2018-08-02 |
| Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants Retrospective database study using administrative claims data - Diphtheria, Acellular Pertussis | Completed | GlaxoSmithKline | 1 | 2013-07-01 | 2015-07-22 | |
| Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults Boostrix - Tetanus, Acellular Pertussis | Phase 3 | Completed | GlaxoSmithKline | 165 | 2013-01-31 | 2018-06-06 |
| Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers Infanrix-IPV+Hib™ - Acellular Pertussis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 321 | 2012-12-08 | 2020-01-21 |
| Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea Infanrix-IPV data collection - Acellular Pertussis, Diphtheria | Completed | GlaxoSmithKline | 645 | 2012-05-21 | 2023-01-27 | |
| Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine Infanrix hexa™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 224 | 2012-04-16 | 2020-01-02 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 657 | 2011-10-14 | 2020-07-17 |
| Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine Infanrix+Hib™, Poliorix™ - Acellular Pertussis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 831 | 2011-10-01 | 2018-06-06 |
| Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents Boostrix TM (new syringe presentation), Boostrix TM (previous syringe presentation) - Diphtheria, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 671 | 2011-07-01 | 2018-08-10 |
| Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Blood Sampling - Tetanus, Poliomyelitis | Phase 4 | Completed | GlaxoSmithKline | 58 | 2011-05-30 | 2021-01-19 |
| Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults BoostrixTM Polio - Acellular Pertussis, Poliomyelitis | Phase 4 | Completed | GlaxoSmithKline | 212 | 2011-04-01 | 2018-06-06 |
| Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children Boostrix PolioTM, RepevaxTM, PriorixTM - Acellular Pertussis, Poliomyelitis | Phase 3 | Completed | GlaxoSmithKline | 387 | 2011-04-01 | 2018-08-17 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine Infanrix™-IPV+Hib, Infanrix™ IPV, Hiberix™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 454 | 2011-03-04 | 2019-11-27 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa™, Prevenar 13®, GSK217744 - Tetanus, Poliomyelitis | Phase 2 | Completed | GlaxoSmithKline | 721 | 2010-12-09 | 2018-08-20 |
Showing 20 of 67. Sign in to see all of them.
Diphtheria (67) · Tetanus (67) · Poliomyelitis (36) · Haemophilus Infections (26) · Hepatitis B (23) · Whooping Cough (10) · Aspergillosis, Allergic Bronchopulmonary (1) · Fever (1) · Influenza, Human (1) · Meningococcal Infections (1) · Pneumococcal Infections (1)
Actinomycetales Infections (67) · Bacterial Infections (67) · Bacterial Infections and Mycoses (67) · Clostridium Infections (67) · Corynebacterium Infections (67) · Gram-Positive Bacterial Infections (67) · Infections (67) · RNA Virus Infections (37) · Virus Diseases (37) · Central Nervous System Diseases (36) · Central Nervous System Infections (36) · Enterovirus Infections (36) · Myelitis (36) · Nervous System Diseases (36) · Neuroinflammatory Diseases (36)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (19) · Boostrix (15) · Diphtheria-Tetanus-acellular Pertussis Vaccines (7) · Tetanus Toxoid (7) · Hiberix (4) · PEDIARIX (4) · Pentetic Acid (4) · 13-valent pneumococcal vaccine (3) · RIX4414 vaccine (3) · DTPa-HBV-IPV combined vaccine (2) · Heptavalent Pneumococcal Conjugate Vaccine (2) · PHiD-CV vaccine (2) · Pneumococcal Vaccines (2) · adacel (2) · 10-valent pneumococcal vaccine (1)
GlaxoSmithKline (67)
United States (12) · China (8) · Finland (8) · Germany (6) · Spain (5) · Australia (4) · Canada (4) · Italy (4) · South Korea (4) · Poland (3) · Belgium (2) · Czechia (2) · Dominican Republic (2) · France (2) · India (2)
PMID 25882172, PMID 28340322, PMID 15882526, PMID 20448468, PMID 21134450, PMID 21945698, PMID 25613716, PMID 26075317, PMID 27902648, PMID 28506516, PMID 29576304, PMID 31776027, PMID 33612341
2014 (2), 2009 (1), 2015 (1)